Rationale and design of the ARAMIS trial: Anakinra versus placebo, a double blind randomized controlled trial for the treatment of acute myocarditis

CONCLUSIONS: ARAMIS is the first trial evaluating inhibition of the interleukin-1β immune innate pathway in the setting of acute myocarditis. Although of small size, it will be the largest randomized trial in acute myocarditis, a serious and poorly studied cardiac condition.PMID:37640625 | DOI:10.1016/j.acvd.2023.07.004

Source: Archives of Cardiovascular Diseases - August 28, 2023 Category: Cardiology Authors: Mathieu Kerneis Fleur Cohen Alain Combes Zahir Amoura Carine Pare Delphine Brugier Etienne Puymirat Jeremie Abtan Benoit Lattuca Jean-Guillaume Dillinger Marie Hauguel-Moreau Johanne Silvain Joe-Elie Salem Estelle Gandjbakhch Guillaume Hekimian Alban Redh Source Type: research